Condition: Breast Cancer · Sponsor: MedSIR
This trial is a multicenter, open-label, non-comparative, phase II, biomarker-driven adjuvant treatment study involving the periodic collection and analysis of blood samples from patients with HR-positive/HER2-negative early-stage BC at higher risk of relapse, who have undergone surgery within the previous five years, with no evidence of locoregional, contralateral, or distant disease. The study design is composed by an initial pre-screening phase, a molecular follow-up phase (ctDNA surveillance phase), and an interventional therapeutic phase (treatment phase). After informed consent is obtained, a total of 976 eligible patients will enter a ctDNA surveillance in which primary tumor tissue and matched normal blood will be collected from each patient to obtain a patient-specific somatic mutations panel (tumor signature). At the event of ctDNA positivity, patients will be screened to enter the treatment phase of the study. Upon confirmed eligibility, a total of 40 patients will be allocated in one of the following trial's arms adopting a sequential recruitment strategy: Arm A: Control Arm (N=10) Arm B: Experimental Arm with giredestrant (N=10) Arm C: Experimental Arm with giredestrant + abemaciclib (N=10) Arm D: Experimental Arm with giredestrant + inavolisib (N=10) If the strategy of ctDNA monitoring enables physicians to identify patients at high risk of relapse and assess whether treatment at molecular relapse can improve outcome, new cohorts may be added to the study.
This description comes directly from the study's public registry record.
Medsir · +34 932 214 135 · contact.trials@medsir.org
Always discuss trial participation with your own doctor first.
| Complejo Hospitalario Universitario A Coruña (CHUAC) | A Coruña, Spain | Recruiting |
| Hospital General Universitario Dr. Balmis | Alicante, Spain | Recruiting |
| Hospital Marina Salud de Denia | Alicante, Spain | Recruiting |
| Hospital Virgen de los Lirios | Alicante, Spain | Recruiting |
| Fundació Althaia | Barcelona, Spain | Recruiting |
| Hospital Clínic i Provincial de Barcelona | Barcelona, Spain | Recruiting |
| Hospital Universitari Dexeus | Barcelona, Spain | Recruiting |
| Hospital Universitario de Basurto | Bilbao, Spain | Recruiting |
| Hospital Provincial de Castellón | Castellon, Spain | Recruiting |
| Hospital Universitario Reina Sofía | Córdoba, Spain | Recruiting |
| Hospital del Vinalopó | Elche, Spain | Recruiting |
| Institut Català d' Oncologia Girona (ICO) | Girona, Spain | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05708235